Dr. Garfinkle will use state-of-the-art genomic technologies to study each individual tumor and immune cell in pediatric rhabdoid tumor patient samples and map the location of these cells in relation to one another, a resolution not previously achieved with traditional genomic studies.
published research
Garfinkle EAR, Perales-Linares R, Gimple RC, Livingstone AJ, Roberts KF, Butt OH, Goedegebuure SP, McLellan MD, Chang GS, Hundal J, Yan J, Navarro JB, Paxton SA, Chattopadhyay S, Cooch N, Perales-Puchalt A, Stavroulaki K, Rochestie S, Peters J, Junker B, Campian JL, Chheda MG, Chicoine MR, Kim AH, Willie JT, Zipfel GJ, Dowling JL, Miller CA, Griffith OL, Griffith M, Gillanders WE, Miller KE, Mardis ER, Sardesai NY, Dunn GP, Johanns TM. Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial. Nat Cancer. 2026.
Kumar R, Neidemire-Colley L, Garfinkle EA, Steere C, Surana S, Murray A, Giordano G, Martin O, Woodbury ED, Rivaldi A, Singh S, Corps K, Lederer K, Karunasiri M, Gorr MW, Wold LE, Sehgal L, Oestreich KJ, Grieselhuber NR, de Lima MJ, Blazar BR, Maillard I, Miller KE, Choe HK, Ranganathan P. BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD. Blood. 2026.
Garfinkle EAR, Mardis ER. Cancer Immunogenomics Approaches and Applications to Cancer Vaccines. Cancer J. 2025.
Kebede AM, Garfinkle EAR, Mathew MT, Varga E, Colace SI, Wheeler G, Kelly BJ, Schieffer KM, Miller KE, Mardis ER, Cottrell CE, Potter SL. Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center. Front Oncol. 2024.